GFAFX
Price
$86.82
Change
+$0.47 (+0.54%)
Updated
Sep 11 closing price
Net Assets
353.07B
NGRDX
Price
$31.90
Change
+$0.23 (+0.73%)
Updated
Sep 11 closing price
Net Assets
2.59B
Interact to see
Advertisement

GFAFX vs NGRDX

GFAFX vs NGRDX Comparison Chart in %
View a ticker or compare two or three
VS
GFAFX vs. NGRDX commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFAFX is a Buy and NGRDX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
GFAFX has more cash in the bank: 353B vs. NGRDX (2.59B). GFAFX pays higher dividends than NGRDX: GFAFX (0.20) vs NGRDX (0.00). GFAFX was incepted earlier than NGRDX: GFAFX (26 years) vs NGRDX (7 years). GFAFX (0.65) is less costly to investors than NGRDX (0.56). GFAFX is a more actively managed with annual turnover of: 32.00 vs. NGRDX (30.00). NGRDX has a lower initial minimum investment than GFAFX: NGRDX (0) vs GFAFX (250). GFAFX annual gain was more profitable for investors over the last year : 0.02 vs. NGRDX (-3.37). GFAFX return over 5 years is better than : 13.04 vs. NGRDX (11.29).
GFAFXNGRDXGFAFX / NGRDX
Total Expense Ratio0.650.55118%
Annual Report Gross Expense Ratio0.650.56116%
Fund Existence26 years7 years-
Gain YTD9.0437.299124%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets353B2.59B13,629%
Annual Yield % from dividends0.200.00-
Returns for 1 year0.02-3.37-1%
Returns for 3 years42.7433.88126%
Returns for 5 years13.0411.29115%
Returns for 10 years106.25N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MSSM58.610.43
+0.73%
Morgan Stanley Pathway Sm-Md Cp Eq ETF
DRUP67.790.36
+0.54%
GraniteShares Nasdaq Sel Disruptors ETF
IOPP26.51N/A
N/A
Simplify Tara India Opportunities ETF
HYXF45.93-0.08
-0.17%
iShares ESG Advanced Hi Yld Corp Bd ETF
XBI156.20-0.62
-0.40%
State Street® SPDR® S&P® Biotech ETF